LO JUNEL FE Drug Patent Profile
✉ Email this page to a colleague
When do Lo Junel Fe patents expire, and what generic alternatives are available?
Lo Junel Fe is a drug marketed by Teva Pharms Inc and is included in one NDA.
The generic ingredient in LO JUNEL FE is ethinyl estradiol; norethindrone acetate. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
US Patents and Regulatory Information for LO JUNEL FE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | LO JUNEL FE | ethinyl estradiol; norethindrone acetate | TABLET;ORAL | 219324-001 | Jun 22, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
